Circulating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular risk

Metabolism. 2014 Oct;63(10):1265-71. doi: 10.1016/j.metabol.2014.06.001. Epub 2014 Jun 9.

Abstract

Objective: Muscle and fat are now recognized as metabolism-regulating endocrine organs. However, muscle and adipocyte-derived novel cytokines such as irisin and omentin-1 remain understudied in relation to metabolic biomarkers that are associated with cardiovascular risk.

Subjects and methods: Thirty-nine subjects with mean (± SD) BMI of 29.2 ± 5.4 kg/m(2) and either diabetes or two other cardiovascular risk factors were enrolled in a 6-month randomized trial of low-dose ethanol. We examined cross-sectional data at baseline, 3-month, and 6-month visits to assess (1) within-person stability of novel cytokines (irisin, omentin-1, visfatin, resistin, and soluble tumor necrosis factor receptor II) and (2) their associations with metabolic parameters, particularly lipoprotein subparticle profile.

Results: Repeated measures of irisin and omentin-1 were highly correlated, with intra-class correlations of 0.84 (95% CI: 0.74, 0.91; P < 0.001) and 0.81 (0.70, 0.89; P < 0.001), respectively. Irisin was negatively correlated with omentin-1 (7.4% irisin decrease per a 1-SD increment in omentin-1; 95% CI: 0.5%, 13.9%; P = 0.04). In models adjusted for age, sex, and race, irisin was negatively associated with HDL cholesterol (7.3% decrease per a 10mg/dL increment; 1.0%, 13.3%; P = 0.02) and large HDL particles (15.5% decrease per a 1-SD or 3.5-μmol/L increment; 5.2%, 24.7%; P=0.005). Omentin-1 was positively associated with mean VLDL size (3.8% increase per a 1-SD increment; 0.06%, 7.8%; P = 0.05). Adjustment for alcohol intervention, BMI, and other cytokines did not materially affect these associations.

Conclusions: Irisin and omentin-1 are stable within-person, inversely associated with each other, and closely related to lipoprotein profile. These molecules may be promising markers for cardiovascular risk.

Keywords: Atherosclerosis; Fibronectin type III domain containing 5; Longitudinal biomarker; Metabolic syndrome; Myokine.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Biomarkers / blood
  • Cardiovascular Diseases / blood*
  • Cross-Sectional Studies
  • Cytokines / blood*
  • Female
  • Fibronectins / blood*
  • GPI-Linked Proteins / blood
  • Humans
  • Lectins / blood*
  • Lipoproteins / blood*
  • Male
  • Middle Aged
  • Resistin / blood
  • Risk Factors

Substances

  • Biomarkers
  • Cytokines
  • FNDC5 protein, human
  • Fibronectins
  • GPI-Linked Proteins
  • ITLN1 protein, human
  • Lectins
  • Lipoproteins
  • Resistin